Federal Drug Administration, USA, Member organizing Committee, FDA workshop AML: Minimal Residual Disease as an Endpoint for Clinical Trials , Workshop March 4, 2013 - White Oak (Ekstern organisation)

Aktivitet: Medlemsskab - typerMedlemskab af udvalg, råd og nævn

Se relationer på Aarhus Universitet

Peter Hokland - Medlem

Member organizing Committee, FDA workshop AML: Minimal Residual Disease as an Endpoint for Clinical Trials , Workshop March 4, 2013 - White Oak
15 dec. 20124 mar. 2013

Ekstern organisation

NavnFederal Drug Administration, USA, Member organizing Committee, FDA workshop AML: Minimal Residual Disease as an Endpoint for Clinical Trials , Workshop March 4, 2013 - White Oak

ID: 51802636